$BOLT
Bolt Biotherapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024096200 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $1.141M $1.275M
YoY Change -54.87% -11.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.799M $4.874M
YoY Change -34.05% -13.29%
% of Gross Profit
Research & Development $13.79M $15.43M
YoY Change -7.8% -1.35%
% of Gross Profit
Depreciation & Amortization $500.0K $400.0K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $17.58M $23.87M
YoY Change -15.1% 12.26%
Operating Profit -$16.44M -$22.60M
YoY Change -9.57% 13.94%
Interest Expense $1.267M $1.402M
YoY Change -34.35% -21.01%
% of Operating Profit
Other Income/Expense, Net $1.267M $1.402M
YoY Change -34.22% -21.01%
Pretax Income -$15.18M -$21.20M
YoY Change -6.67% 17.38%
Income Tax
% Of Pretax Income
Net Earnings -$15.18M -$21.20M
YoY Change -6.65% 17.38%
Net Earnings / Revenue -1330.06% -1662.35%
Basic Earnings Per Share -$0.40 -$0.56
Diluted Earnings Per Share -$0.40 -$0.56
COMMON SHARES
Basic Shares Outstanding 38.26M 38.13M
Diluted Shares Outstanding 38.25M 38.13M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $53.80M $73.70M
YoY Change -55.06% -41.45%
Cash & Equivalents $9.366M $6.202M
Short-Term Investments $44.43M $67.50M
Other Short-Term Assets $3.349M $2.934M
YoY Change -41.25% -38.9%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $57.15M $76.63M
YoY Change -54.45% -41.35%
LONG-TERM ASSETS
Property, Plant & Equipment $3.565M $4.079M
YoY Change -32.3% -27.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $30.60M $23.83M
YoY Change 41.66% -23.66%
Other Assets $287.0K $308.0K
YoY Change -78.61% -69.57%
Total Long-Term Assets $52.19M $47.55M
YoY Change 4.61% -20.8%
TOTAL ASSETS
Total Short-Term Assets $57.15M $76.63M
Total Long-Term Assets $52.19M $47.55M
Total Assets $109.3M $124.2M
YoY Change -37.65% -34.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.482M $2.627M
YoY Change -59.75% -23.54%
Accrued Expenses $14.63M $13.25M
YoY Change 11.68% 6.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.08M $17.90M
YoY Change -3.56% 1.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.08M $17.90M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $37.30M $38.32M
YoY Change -20.79% -21.1%
SHAREHOLDERS EQUITY
Retained Earnings -$411.5M -$396.3M
YoY Change 18.79% 20.05%
Common Stock $483.3M $482.2M
YoY Change 1.79% 2.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $72.03M $85.86M
YoY Change
Total Liabilities & Shareholders Equity $109.3M $124.2M
YoY Change -37.65% -34.88%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$15.18M -$21.20M
YoY Change -6.65% 17.38%
Depreciation, Depletion And Amortization $500.0K $400.0K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$13.97M -$16.14M
YoY Change -16.62% 6.82%
INVESTING ACTIVITIES
Capital Expenditures $41.00K $0.00
YoY Change -74.38% -100.0%
Acquisitions
YoY Change
Other Investing Activities $17.18M $18.00M
YoY Change 34.0% 32.26%
Cash From Investing Activities $17.14M $18.00M
YoY Change 35.37% 32.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 79.00K
YoY Change -46.26%
NET CHANGE
Cash From Operating Activities -13.97M -16.14M
Cash From Investing Activities 17.14M 18.00M
Cash From Financing Activities 0.000 79.00K
Net Change In Cash 3.172M 1.940M
YoY Change -177.56% -240.07%
FREE CASH FLOW
Cash From Operating Activities -$13.97M -$16.14M
Capital Expenditures $41.00K $0.00
Free Cash Flow -$14.01M -$16.14M
YoY Change -17.17% 6.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001641281
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39988
dei Entity Registrant Name
EntityRegistrantName
Bolt Biotherapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2804636
dei Entity Address Address Line1
EntityAddressAddressLine1
900 Chesapeake
dei Entity Address Address Line2
EntityAddressAddressLine2
Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94063
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
665-9295
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value
dei Trading Symbol
TradingSymbol
BOLT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38264843
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6202000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10810000
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
67495000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
91379000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2934000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3519000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
76631000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
105708000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4079000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4957000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17559000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19120000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1765000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1765000
CY2024Q2 us-gaap Long Term Investments
LongTermInvestments
23834000
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
26413000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
308000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1821000
CY2024Q2 us-gaap Assets
Assets
124176000
CY2023Q4 us-gaap Assets
Assets
159784000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2627000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2987000
CY2024Q2 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
10254000
CY2023Q4 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12486000
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2024000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2201000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2995000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2782000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17900000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20456000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15896000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17437000
CY2024Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4520000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
9107000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43000
CY2024Q2 us-gaap Liabilities
Liabilities
38316000
CY2023Q4 us-gaap Liabilities
Liabilities
47043000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38264843
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38264843
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38114606
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38114606
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
482194000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
476988000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-44000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
37000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396291000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-364285000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
85860000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
112741000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124176000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
159784000
CY2024Q2 us-gaap Revenues
Revenues
1275000
CY2023Q2 us-gaap Revenues
Revenues
1433000
us-gaap Revenues
Revenues
6549000
us-gaap Revenues
Revenues
3259000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15433000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15644000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31962000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30269000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4874000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5621000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10711000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11237000
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
3565000
us-gaap Restructuring Charges
RestructuringCharges
3565000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
23872000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
21265000
us-gaap Operating Expenses
OperatingExpenses
46238000
us-gaap Operating Expenses
OperatingExpenses
41506000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22597000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19832000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39689000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38247000
CY2024Q2 us-gaap Investment Income Net
InvestmentIncomeNet
1402000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
1775000
us-gaap Investment Income Net
InvestmentIncomeNet
3008000
us-gaap Investment Income Net
InvestmentIncomeNet
3210000
us-gaap Other Income
OtherIncome
4675000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1402000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1775000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7683000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3210000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21195000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18057000
us-gaap Net Income Loss
NetIncomeLoss
-32006000
us-gaap Net Income Loss
NetIncomeLoss
-35037000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-81000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
690000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21203000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18051000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32087000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34347000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38128344
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38128344
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37750393
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37750393
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38098383
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38098383
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37717391
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37717391
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
104159000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
79000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2825000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21195000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
85860000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
157686000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
141000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2350000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18057000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
142132000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
112741000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
79000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5127000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-81000
us-gaap Net Income Loss
NetIncomeLoss
-32006000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
85860000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
171506000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
141000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4826000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
690000
us-gaap Net Income Loss
NetIncomeLoss
-35037000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
142132000
us-gaap Profit Loss
ProfitLoss
-32006000
us-gaap Profit Loss
ProfitLoss
-35037000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
915000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
925000
us-gaap Share Based Compensation
ShareBasedCompensation
5127000
us-gaap Share Based Compensation
ShareBasedCompensation
4826000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1824000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1964000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1561000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1450000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2098000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
928000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2629000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5428000
bolt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1328000
bolt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1139000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4764000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1217000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-43000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32893000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38511000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
55283000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
96524000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
83489000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
139130000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28206000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42571000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
79000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
147000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
79000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
147000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4608000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4207000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12575000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10809000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7967000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15016000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6202000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13451000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1765000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1565000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7967000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15016000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
37000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
46000
bolt Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
102000
bolt Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
102000
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
97500000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, stock-based compensation, restructuring costs, long-lived assets impairment assessment, and accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. As of June 30, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, most of the Company’s funds were invested with a registered investment manager and custodied at one financial institution, with operating cash kept at a separate financial institution, and account balances may at times exceed federally insured limits. Management believes that the Company is not subject to unusual or significant credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
94336000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
56000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
94292000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
117756000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
89000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
53000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
117792000
CY2024Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0
CY2024Q2 bolt Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Estimated Fair Valued
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsEstimatedFairValued
48121000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
21000
CY2024Q2 bolt Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Estimated Fair Value
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerEstimatedFairValue
46171000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
35000
CY2024Q2 bolt Debt Securities Available For Sale Unrealized Loss Position Estimated Fair Value
DebtSecuritiesAvailableForSaleUnrealizedLossPositionEstimatedFairValue
94292000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
56000
CY2023Q4 bolt Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Estimated Fair Valued
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsEstimatedFairValued
71178000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
12000
CY2023Q4 bolt Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Estimated Fair Value
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerEstimatedFairValue
46614000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
41000
CY2023Q4 bolt Debt Securities Available For Sale Unrealized Loss Position Estimated Fair Value
DebtSecuritiesAvailableForSaleUnrealizedLossPositionEstimatedFairValue
117792000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
53000
CY2024Q2 bolt Accrued Interest Receivable On Available For Sale Securities
AccruedInterestReceivableOnAvailableForSaleSecurities
400000
CY2023Q4 bolt Accrued Interest Receivable On Available For Sale Securities
AccruedInterestReceivableOnAvailableForSaleSecurities
300000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10747000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10709000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6668000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5752000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4079000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4957000
CY2024Q2 us-gaap Depreciation
Depreciation
400000
CY2023Q2 us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
900000
us-gaap Depreciation
Depreciation
900000
CY2024Q2 bolt Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
4019000
CY2023Q4 bolt Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
6092000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2889000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5820000
CY2024Q2 bolt Accrued Restructuring Charges
AccruedRestructuringCharges
2900000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
446000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
574000
CY2024Q2 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
10254000
CY2023Q4 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12486000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y4M24D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.112
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.111
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1119000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1119000
us-gaap Operating Lease Cost
OperatingLeaseCost
2239000
us-gaap Operating Lease Cost
OperatingLeaseCost
2239000
us-gaap Operating Lease Payments
OperatingLeasePayments
2411000
us-gaap Operating Lease Payments
OperatingLeasePayments
2332000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2475000
CY2024Q2 bolt Lessee Operating Sublease Income Receivable Remainder Of Fiscal Year
LesseeOperatingSubleaseIncomeReceivableRemainderOfFiscalYear
183000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4340000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3484000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3602000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3724000
CY2024Q2 bolt Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
9514000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
27139000
CY2024Q2 bolt Lessee Operating Sublease Income
LesseeOperatingSubleaseIncome
183000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
8248000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
18891000
us-gaap Sublease Income
SubleaseIncome
183000
bolt Potential Future Milestone Payments
PotentialFutureMilestonePayments
0
CY2024Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.50
CY2024Q2 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
3600000
CY2024Q2 us-gaap Payments For Restructuring
PaymentsForRestructuring
0
us-gaap Payments For Restructuring
PaymentsForRestructuring
0
CY2024Q2 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
0
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
0
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
2900000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2825000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2350000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5127000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4826000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21195000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18057000
us-gaap Net Income Loss
NetIncomeLoss
-32006000
us-gaap Net Income Loss
NetIncomeLoss
-35037000
CY2024Q2 bolt Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
38164856
CY2023Q2 bolt Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
37851141
bolt Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
38141318
bolt Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
37826508
CY2024Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
36512
CY2023Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
100748
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
42935
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
109117
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38128344
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38128344
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37750393
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37750393
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38098383
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38098383
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37717391
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37717391
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12626999
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10884085

Files In Submission

Name View Source Status
0000950170-24-096200-index-headers.html Edgar Link pending
0000950170-24-096200-index.html Edgar Link pending
0000950170-24-096200.txt Edgar Link pending
0000950170-24-096200-xbrl.zip Edgar Link pending
bolt-20240630.htm Edgar Link pending
bolt-20240630.xsd Edgar Link pending
bolt-ex31_1.htm Edgar Link pending
bolt-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bolt-20240630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable